Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Both stocks have made significant breakthroughs. Among the qualities a biotech company needs to be successful, being innovative is one of the most important. It's easy to understand why. Although ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC ...

Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior ...

Wang covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Alnylam Pharma, and Vertex Pharmaceuticals ... development and commercialization of human therapeutic drugs using ...

Viking Therapeutics reported updated, early-stage study results on its oral obesity drug candidate. Vertex Pharmaceuticals ...

Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

Casgevy was developed in collaboration with narrow-moat Vertex Pharmaceuticals for the treatment of two blood disease: transfusion-dependent beta-thalassemia and sickle-cell anemia. Casgevy received ...